Thai diabetes app shows little extra HbA1c benefit over standard education
Key takeaway:
In a 6-month randomized trial of 129 adults with uncontrolled type 2 diabetes, a Thai-language self-management app did not lower HbA1c more than standard education alone, although fasting plasma glucose improved in participants younger than 65 years.
Study at a glance
Study type
RCTs
duration
Medium-Term (3–12 mo)
Intervention
Rama App
Outcomes
HbA1c, Fasting Plasma Glucose, Self-management behaviors
Funding
Non-industry sponsored
What was studied
A Thai-language diabetes self-management app added to standard outpatient education.
What they found
- HbA1c ↓ in both groups, with no clear added benefit from the app
- Fasting plasma glucose ↓ in participants younger than 65 years using the app
- DSMES score ↑ during follow-up in the app group
mainEffects
HbA1c ↓ in both groups, with no clear added benefit from the app
Fasting plasma glucose ↓ in participants younger than 65 years using the app
DSMES score ↑ during follow-up in the app group
Evidence Suggest
- At 6 months, mean HbA1c was 7.8% in the app group and 8.1% in the control group, but the between-group difference was not statistically significant.
- Fasting plasma glucose was significantly lower at 6 months in the subgroup younger than 65 years assigned to the app.
- The intervention group showed significantly higher DSMES scores from baseline to 6 months, suggesting support for self-management behaviors.
Who this applies to
These findings apply most directly to adults with uncontrolled type 2 diabetes in outpatient care who can use a smartphone. The results are especially relevant to Thai or similar Asian settings where local food databases may improve the usefulness of nutrition tracking.
Keep in Mind
The app was tested on top of diabetes self-management education and support, not instead of it. Because both groups received education, the study mainly shows whether the app adds extra benefit beyond usual structured care. The main HbA1c result was not clearly different, and the strongest glucose signal appeared in a younger subgroup.
Between the Lines
- This was a single-center study with 129 participants.
- The trial was open label, so participant behavior may have been influenced by knowing group assignment.
- Six-month analyses excluded participants with missing outcome data rather than using full intention-to-treat methods.
- Average app adherence was moderate, which may have limited the size of any benefit.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Sources
Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes—2025
Abaloparatide Followed by Alendronate Shows Promising Results for Women With Osteoporosis, T2D | American Association of Clinical Endocrinology
Connecting the Dots: Diabetes, CKD, and CVD Pathways | American Association of Clinical Endocrinology
Episode 39: AACE 2023 Updated Comprehensive Type 2 Diabetes Management Algorithm | American Association of Clinical Endocrinology
Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease | American Association of Clinical Endocrinology
Non-Insulin Injectable Therapies for Diabetes Management | American Association of Clinical Endocrinology
mHealth: new horizons for health through mobile technologies
Manage Blood Sugar
Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis.
Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.
The role of peripheral blood HIF-1α in pancreatic β-cell dysfunction and insulin resistance among patients with type 2 diabetes: a systematic review and meta-analysis.
No ads. No tracking
A clean, privacy-first research experience.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.